Clinical trials: Glioblastoma Multiforme
Glioblastoma
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
- Trial name
- NCT00948389
- Testing
- Dasatinib, Lomustine
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Bristol-Myers Squibb
Adult Glioblastoma, Adult Gliosarcoma
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
This randomized phase II trial is studying the side effects and how well giving bevacizumab together with irinotecan or temozolomide works in treating patients with recurrent or refractory glioblastoma multiforme or gliosarcoma.
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00433381
- Testing
- Bevacizumab, Irinotecan Hydrochloride, Temozolomide
- Where
- 93 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Recurrent Glioblastoma Multiforme, Malignant Glioma
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both…
- Conditions
- Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
- Trial name
- NCT01738646
- Testing
- Vorinostat, Bevacizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00486603
- Testing
- hydroxychloroquine, temozolomide, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme, Glioma of Brain
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose…
- Trial name
- NCT03834740
- Testing
- Ribociclib, Everolimus
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Adult Giant Cell Glioblastoma, Adult Glioblastoma
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01894061
- Testing
- Bevacizumab, NovoTTF-l00A, Quality of Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma Multiforme
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
In this phase I/II study,investigators are evaluating the feasibility and efficacy of the combination of BKM120, an oral inhibitor of PI3 kinase, and bevacizumab in the treatment of patients with relapsed/refractory GBM.
- Trial name
- NCT01349660
- Testing
- Bevacizumab, BKM120
- Where
- 8 sites in United States
- Volunteers
- 88 people
- Sponsor
- SCRI Development Innovations, LLC
Adult Brain Glioblastoma, Glioblastoma Multiforme
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
- Trial name
- NCT02078648
- Testing
- SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- Stemline Therapeutics, Inc.
Glioblastoma
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01310868
- Testing
- 5-ALA, Gliadel wafers, Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
- Where
- 10 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- University College, London
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
High Grade Gliomas, Brain Tumors
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Background: Radiation therapy with temozolomide (an anti-cancer drug) is standard therapy for treating brain tumors called glioblastomas.
- Trial name
- NCT00302159
- Testing
- adjuvant therapy, Temozolomide, Valproic Acid
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Intracranial Tumors, Glioblastoma
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called [11C] PBR28a, which is also known as peripheral…
- Conditions
- Intracranial Tumors, Glioblastoma, Melanoma
- Trial name
- NCT02431572
- Testing
- PBR PET, Cancer Immunotherapy, Radiation and chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Anaplastic Astrocytoma, Anaplastic Ependymoma
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma
- Trial name
- NCT01836549
- Testing
- imetelstat sodium
- Where
- 11 sites in United States
- Volunteers
- 43 people
- Sponsor
- Pediatric Brain Tumor Consortium
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01478321
- Testing
- Temozolomide, hypofractionated radiation therapy, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme
Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
The purpose of the protocol was to induce a novel radiochemotherapy with enzastaurin as first-line treatment regimen in glioblastoma: Participants with active, unmethylated MGMT promoter were treated with enzastaurin before…
- Trial name
- NCT00509821
- Testing
- Enzastaurin 500 milligram (mg) Once Daily (QD), Enzastaurin 250 mg Twice Daily (BID)
- Where
- 10 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
RECURRENT GLIOBLASTOMA, Brain Tumor
Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
This protocol is designed to generate and provide preliminary data to determine the safety and activity of combination therapy using tumor treating fields (TTFields; Optune(NovoTTF-100A); Novocure, Haifa, Israel), a novel…
- Trial name
- NCT01925573
- Testing
- Optune(NOVOTTF-100A)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
Brain and Central Nervous System Tumors
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00998010
- Testing
- bortezomib + temozolomide+ radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy.
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma
- Trial name
- NCT00042991
- Testing
- gefitinib, radiation therapy, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)